News
Eisai, Biogen face delay to subcutaneous Leqembi
Eisai and Biogen are facing a delay in the FDA review of injectable Leqembi for initial dosing in Alzheimer's, viewed as a key growth driver.
Market Access
Views from Asembia: EVERSANA's take on outsourcing, AI, and ...
Following Asembia 2026, pharmaphorum spoke with Krista Pinto, a leading commercialisation expert at EVERSANA.
News
Lilly inflates US facility investment spending by $4.5bn
Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.
Market Access
Anglonordic Life Science 2026: A focus on execution
The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.
News
Pfizer, Arvinas join SERD club with Veppanu approval
Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
